IOVAIovance Biotherapeutics, Inc.Not started yet
A Study of IOV-5001 in Adults With Advanced Solid Tumors
Advanced Solid Tumors · Non-Small Cell Lung Cancer · Triple Negative Breast Cancer (TNBC) · Colorectal Cancer · Head and Neck Squamous Cell Carcinoma · Metastatic Solid Tumors · Unresectable Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 106 (planned)
- Started
- Sep 2026
- Main results expected
- Mar 2034
- Fully finished
- Mar 2044
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Safety Assessment
Measured over: Up to 30 days
Phase 2: Efficacy Measured by Overall Response Rate (ORR)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07743723 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC